Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602425744> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2602425744 abstract "6559 Background: The New Drug Funding Program (NDFP) is an IV-based government funded provincial formulary that reimburses over 90 Ontario hospitals for new and expensive anti-cancer and supportive care drugs. An expert committee considers clinical and economic evidence, including a hierarchy of benefits and evidence to inform decisions. There can be extended unpredictable delays from the time evidence is available to funding, during which hospitals decide whether to pay for therapies. This report assesses hospitals’ willingness to pay for HRPC therapies prior to a funding decision. Methods: Patterns of uptake for docetaxel (D) and zoledronic acid (Z) were analyzed from the NDFP database and compared to publication dates, hierarchy of benefits and evidence, and costs for these new HRPC therapies. Results: Analysis of NDFP data for patterns of uptake revealed an apparent cost shift from hospitals to the NDFP for D but not for Z once funding was in place. This cost shift demonstrated that despite a higher cost, shorter time from publication to funding and equivalent levels of evidence that hospitals paid for D but not for Z. The only factor that favored payment for D over Z was that D ranked higher than Z in the NDFP hierarchy of benefits: Survival was the primary outcome for D versus prevention of skeletal related events (SRE) for Z. Publication of provincial practice guidelines supporting these therapies occurred after NDFP funding was in place and would not have impacted hospitals’ decisions to pay. Despite immediate uptake of Z once NDFP funding was introduced, hospitals did not absorb the cost when funding was temporarily suspended for a 5 month period. Conclusions: Survival benefit appeared to be the primary factor impacting hospitals’ willingness to pay for unfunded HRPC therapies. This observation is consistent with the ranking of clinical benefits used to inform NDFP formulary decisions. The higher cost of D did not appear to impact hospitals’ willingness to pay. No significant financial relationships to disclose. [Table: see text]" @default.
- W2602425744 created "2017-04-07" @default.
- W2602425744 creator A5002860158 @default.
- W2602425744 creator A5047113165 @default.
- W2602425744 creator A5065390373 @default.
- W2602425744 date "2007-06-20" @default.
- W2602425744 modified "2023-09-27" @default.
- W2602425744 title "Willingness to pay for new hormone-refractory prostate cancer (HRPC) therapies: Experience from Ontario hospitals" @default.
- W2602425744 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.6559" @default.
- W2602425744 hasPublicationYear "2007" @default.
- W2602425744 type Work @default.
- W2602425744 sameAs 2602425744 @default.
- W2602425744 citedByCount "0" @default.
- W2602425744 crossrefType "journal-article" @default.
- W2602425744 hasAuthorship W2602425744A5002860158 @default.
- W2602425744 hasAuthorship W2602425744A5047113165 @default.
- W2602425744 hasAuthorship W2602425744A5065390373 @default.
- W2602425744 hasConcept C100406419 @default.
- W2602425744 hasConcept C121608353 @default.
- W2602425744 hasConcept C126322002 @default.
- W2602425744 hasConcept C138885662 @default.
- W2602425744 hasConcept C159110408 @default.
- W2602425744 hasConcept C162324750 @default.
- W2602425744 hasConcept C175444787 @default.
- W2602425744 hasConcept C2777364431 @default.
- W2602425744 hasConcept C2778137410 @default.
- W2602425744 hasConcept C2779598192 @default.
- W2602425744 hasConcept C2780192828 @default.
- W2602425744 hasConcept C2781190966 @default.
- W2602425744 hasConcept C41895202 @default.
- W2602425744 hasConcept C512399662 @default.
- W2602425744 hasConcept C71924100 @default.
- W2602425744 hasConceptScore W2602425744C100406419 @default.
- W2602425744 hasConceptScore W2602425744C121608353 @default.
- W2602425744 hasConceptScore W2602425744C126322002 @default.
- W2602425744 hasConceptScore W2602425744C138885662 @default.
- W2602425744 hasConceptScore W2602425744C159110408 @default.
- W2602425744 hasConceptScore W2602425744C162324750 @default.
- W2602425744 hasConceptScore W2602425744C175444787 @default.
- W2602425744 hasConceptScore W2602425744C2777364431 @default.
- W2602425744 hasConceptScore W2602425744C2778137410 @default.
- W2602425744 hasConceptScore W2602425744C2779598192 @default.
- W2602425744 hasConceptScore W2602425744C2780192828 @default.
- W2602425744 hasConceptScore W2602425744C2781190966 @default.
- W2602425744 hasConceptScore W2602425744C41895202 @default.
- W2602425744 hasConceptScore W2602425744C512399662 @default.
- W2602425744 hasConceptScore W2602425744C71924100 @default.
- W2602425744 hasLocation W26024257441 @default.
- W2602425744 hasOpenAccess W2602425744 @default.
- W2602425744 hasPrimaryLocation W26024257441 @default.
- W2602425744 hasRelatedWork W17862392 @default.
- W2602425744 hasRelatedWork W1992953263 @default.
- W2602425744 hasRelatedWork W2003372003 @default.
- W2602425744 hasRelatedWork W2040968093 @default.
- W2602425744 hasRelatedWork W2087582093 @default.
- W2602425744 hasRelatedWork W2295052671 @default.
- W2602425744 hasRelatedWork W2602425744 @default.
- W2602425744 hasRelatedWork W3134636591 @default.
- W2602425744 hasRelatedWork W3159044365 @default.
- W2602425744 hasRelatedWork W2189507417 @default.
- W2602425744 isParatext "false" @default.
- W2602425744 isRetracted "false" @default.
- W2602425744 magId "2602425744" @default.
- W2602425744 workType "article" @default.